Zdenek Spacil1, Arun Babu Kumar2, Hsuan-Chieh Liao2, Christiane Auray-Blais3, Samantha Stark4, Teryn R Suhr5, C Ronald Scott6, Frantisek Turecek2, Michael H Gelb7. 1. Department of Chemistry, gelb@chem.washington.edu spacil@u.washington.edu. 2. Department of Chemistry. 3. Clinical Research Center, Centre Hospitalier Universitaire de Sherbrooke, and Université de Sherbrooke, Sherbrooke, Quebec, Canada; 4. National Referral Laboratory, Genetics and Molecular Pathology, South Australia Pathology, Women's and Children's Hospital, Adelaide, Australia; 5. MLD Foundation, West Linn, OR. 6. Department of Pediatrics, and. 7. Department of Chemistry, Department of Biochemistry, University of Washington, Seattle, WA; gelb@chem.washington.edu spacil@u.washington.edu.
Abstract
BACKGROUND: Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder caused by deficiency in arylsulfatase A activity, leading to accumulation of sulfatide substrates. Diagnostic and monitoring procedures include demonstration of reduced arylsulfatase A activity in peripheral blood leukocytes or detection of sulfatides in urine. However, the development of a screening test is challenging because of instability of the enzyme in dried blood spots (DBS), the widespread occurrence of pseudodeficiency alleles, and the lack of available urine samples from newborn screening programs. METHODS: We measured individual sulfatide profiles in DBS and dried urine spots (DUS) from MLD patients with LC-MS/MS to identify markers with the discriminatory power to differentiate affected individuals from controls. We also developed a method for converting all sulfatide molecular species into a single species, allowing quantification in positive-ion mode upon derivatization. RESULTS: In DBS from MLD patients, we found up to 23.2-fold and 5.1-fold differences in total sulfatide concentrations for early- and late-onset MLD, respectively, compared with controls and pseudodeficiencies. Corresponding DUS revealed up to 164-fold and 78-fold differences for early- and late-onset MLD patient samples compared with controls. The use of sulfatides converted to a single species simplified the analysis and increased detection sensitivity in positive-ion mode, providing a second option for sulfatide analysis. CONCLUSIONS: This study of sulfatides in DBS and DUS suggests the feasibility of the mass spectrometry method for newborn screening of MLD and sets the stage for a larger-scale newborn screening pilot study.
BACKGROUND:Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder caused by deficiency in arylsulfatase A activity, leading to accumulation of sulfatide substrates. Diagnostic and monitoring procedures include demonstration of reduced arylsulfatase A activity in peripheral blood leukocytes or detection of sulfatides in urine. However, the development of a screening test is challenging because of instability of the enzyme in dried blood spots (DBS), the widespread occurrence of pseudodeficiency alleles, and the lack of available urine samples from newborn screening programs. METHODS: We measured individual sulfatide profiles in DBS and dried urine spots (DUS) from MLDpatients with LC-MS/MS to identify markers with the discriminatory power to differentiate affected individuals from controls. We also developed a method for converting all sulfatide molecular species into a single species, allowing quantification in positive-ion mode upon derivatization. RESULTS: In DBS from MLDpatients, we found up to 23.2-fold and 5.1-fold differences in total sulfatide concentrations for early- and late-onset MLD, respectively, compared with controls and pseudodeficiencies. Corresponding DUS revealed up to 164-fold and 78-fold differences for early- and late-onset MLDpatient samples compared with controls. The use of sulfatides converted to a single species simplified the analysis and increased detection sensitivity in positive-ion mode, providing a second option for sulfatide analysis. CONCLUSIONS: This study of sulfatides in DBS and DUS suggests the feasibility of the mass spectrometry method for newborn screening of MLD and sets the stage for a larger-scale newborn screening pilot study.
Authors: Christiane Auray-Blais; David S Millington; Caroline Barr; Sarah P Young; Kevin Mills; Joe T R Clarke Journal: Mol Genet Metab Date: 2009-04-18 Impact factor: 4.797
Authors: Xinying Hong; Arun Babu Kumar; Jessica Daiker; Fan Yi; Martin Sadilek; Fabiola De Mattia; Francesca Fumagalli; Valeria Calbi; Roberta Damiano; Maria Della Bona; Giancarlo la Marca; Adeline L Vanderver; Amy T Waldman; Laura Adang; Omar Sherbini; Sarah Woidill; Teryn Suhr; Joanne Kurtzberg; Maria L Beltran-Quintero; Maria Escolar; Alessandro Aiuti; Alan Finglas; Amber Olsen; Michael H Gelb Journal: Anal Chem Date: 2020-04-16 Impact factor: 6.986
Authors: Robert Jirásko; Michal Holčapek; Maria Khalikova; David Vrána; Vladimír Študent; Zuzana Prouzová; Bohuslav Melichar Journal: J Am Soc Mass Spectrom Date: 2017-03-30 Impact factor: 3.109
Authors: Maria Blomqvist; Jan Borén; Henrik Zetterberg; Kaj Blennow; Jan-Eric Månsson; Marcus Ståhlman Journal: J Lipid Res Date: 2017-05-26 Impact factor: 5.922